New AI-driven diagnostics technique could transform treatment for bowel cancer
Apr 27 2021
A test which uses artificial intelligence (AI) to measure proteins present in some patients with advanced bowel cancer could hold the key to more targeted treatment, according to research published today.
Image Credit: University of Leeds
A team at the University of Leeds collaborated with researchers at Roche Diagnostics to develop the technique, which will help doctors and patients to decide on the best treatment options.
They used samples from a previous trial funded by Cancer Research UK to look at the levels of two proteins, known as AREG and EREG, which are produced by some colorectal cancers.
New AI-Based Method Could Enable Better Treatment of Advanced Bowel Cancer
Written by AZoRoboticsApr 23 2021
A new study reports that a test that employs artificial intelligence (AI) to measure proteins found in certain patients suffering from advanced bowel cancer could enable more targeted treatment.
The main image is of a colorectal cancer. To the left of the black line is how the image would appear down a microscope. The image to the right of the line is how it would look once the artificial intelligence algorithm has been used to label the cancer cells with dots. The red dots highlight the cells which contain the EREG protein and the green dots are EREG negative. Image Credit: Copyright Roche Diagnostics.
E-Mail
A test which uses artificial intelligence (AI) to measure proteins present in some patients with advanced bowel cancer could hold the key to more targeted treatment, according to research published today.
A team at the University of Leeds collaborated with researchers at Roche Diagnostics to develop the technique, which will help doctors and patients to decide on the best treatment options.
They used samples from a previous trial funded by Cancer Research UK to look at the levels of two proteins, known as AREG and EREG, which are produced by some colorectal cancers.
Algorithms driven by AI enabled the researchers to show that patients with higher levels of these proteins received significant benefit from a treatment which inhibits a different protein involved in cancer cell growth, known as EGFR. Of equal importance, patients with low levels of the proteins did not benefit from the treatment.